Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Tuberculosis Therapeutics Market from 2024 to 2025?

There has been a significant increase in the size of the tuberculosis therapeutics market in the past few years. The market is projected to rise from $1.88 billion in 2024 to $2.01 billion in 2025, with a compound annual growth rate (CAGR) of 6.58%. This past growth has been spurred by factors such as the increasing prevalence of tuberculosis, greater use of tuberculosis therapeutics, heightened awareness about tuberculosis (TB), the rising instances of XDR-TB, and the growing number of drug-resistant tuberculosis cases.

What Is the Projected Market Size of the Tuberculosis Therapeutics Market?

Expectations for substantial growth in the size of the tuberculosis therapeutics market can be anticipated in the coming years. The market is projected to expand to a whopping $2.57 billion by 2029, escalating at a compound annual growth rate (CAGR) of 6.32%. Factors contributing to this surge in the forecast period could include upsurge in healthcare infrastructure investments, expanded awareness and education, an increase in research and development investments, a higher rate of product approvals for various anti-TB agents, greater research funding, and a rising geriatric population. The forecast period is also set to observe major trends such as improvements in drug development, personalized treatments, combination therapies, digital health solutions, AI, and machine learning for medicinal discovery.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20983&type=smp

Who are the Major Competitors in the Tuberculosis Therapeutics Market Outlook?

Major companies operating in the tuberculosis therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Macleods Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Alkem Laboratories Limited, Emcure Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., Sequella Inc.

What Is Fueling Growth in the Tuberculosis Therapeutics Market?

The surge in concurrent infection rates (TB-HIV) are predicted to fuel the expansion of the tuberculosis therapeutics market. Concurrent infection rates (TB-HIV) denote the proportion of people who are concurrently afflicted with tuberculosis (TB) and the human immunodeficiency virus (HIV). An increase in concurrent infection rates (TB-HIV) results from the compromised immune system instigated by HIV, rendering individuals increasingly vulnerable to tuberculosis, adding to the global intersection of both epidemics among high-risk groups. Tuberculosis therapeutics tackle increasing concurrent infection rates (TB-HIV) by providing specialized treatments that tackle both TB infection and HIV-induced immune suppression, enhancing patient prognosis overall and lessening the impact of both illnesses. As an example, the gov.uk, a UK-based public body, reported in October 2023 that there were 3,805 new HIV diagnoses in England in 2022, which is a rise of 22% from the 3,118 cases logged in 2021. Thus, the growing concurrent infection rates (TB-HIV) are impacting the expansion of the tuberculosis therapeutics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20983&type=smp

Which Tuberculosis Therapeutics Market Segments Are Growing the Fastest?

The tuberculosis therapeutics market covered in this report is segmented –

1) By Type: Active Tuberculosis (TB), Latent Tuberculosis (TB)

2) By Product Type: Isoniazid, Rifampin, Pyrazinamide, Hydrazine derivatives, Miscellaneous anti-tubercular drugs, Ethambutol

3) By Route of Administration: Oral, Parenteral, Other route of administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Active Tuberculosis (TB): First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol), Second-Line Drugs (Fluoroquinolones, Aminoglycosides), Combination Therapies, Drug-Resistant TB Treatments (MDR-TB, XDR-TB)

2) By Latent Tuberculosis (TB): Isoniazid Prophylaxis, Rifampicin-Based Regimens, Rifapentine-Based Regimens, Combination Prophylactic Therapies

Which Industry Trends Are Shaping the Future of the Tuberculosis Therapeutics Market?

Major players in the tuberculosis therapeutics market are pivoting towards creating innovative solutions such as combined therapy to enhance treatment effectiveness, shorten therapy durations, and battle drug-resistant tuberculosis strains. The term combined therapy describes the utilization of two or more drugs from different categories to manage a disease, with the aim of boosting treatment effectiveness, lowering resistance and enhancing patient results. For example, in July 2024, Johnson & Johnson, an American pharmaceutical firm, reached a pivotal landmark in tuberculosis treatment with both the U.S. FDA and the European Commission approving SIRTURO (bedaquiline). This groundbreaking drug, the first specifically developed to combat multidrug-resistant tuberculosis (MDR-TB) in more than 40 years, uses a distinct mechanism that inhibits the ATP synthase enzyme vital to the energy production of TB bacteria, thus offering a targeted and efficient therapeutic strategy. Its inclusion in combined therapies augments the overall efficacy of MDR-TB protocols, shortens treatment duration, and improves patient adherence.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/tuberculosis-therapeutics-global-market-report

Which Countries Are Leading the Tuberculosis Therapeutics Market?

North America was the largest region in the tuberculosis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tuberculosis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20983

This Report Delivers Insight On:

1. How big is the tuberculosis therapeutics market, and how is it changing globally?

2. Who are the major companies in the tuberculosis therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the tuberculosis therapeutics market right now?

4. Which products or customer segments are growing the most in the tuberculosis therapeutics market?

5. What factors are helping or slowing down the growth of the tuberculosis therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model